Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
about
Development of NS3/4A Protease-Based Reporter Assay Suitable for Efficiently Assessing Hepatitis C Virus InfectionDiscovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV)X-ray structure and inhibition of the feline infectious peritonitis virus 3C-like protease: Structural implications for drug designDynamically-driven inactivation of the catalytic machinery of the SARS 3C-like protease by the N214A mutation on the extra domainDynamically-driven enhancement of the catalytic machinery of the SARS 3C-like protease by the S284-T285-I286/A mutations on the extra domain.New in silico and conventional in vitro approaches to advance HIV drug discovery and design.Investigation of antimicrobial and protease-inhibitory activity from cultured cyanobacteria.In Silico screening on the three-dimensional model of the Plasmodium vivax SUB1 protease leads to the validation of a novel anti-parasite compoundIdentification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screeningsLigand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.Temperature-sensitive mutants and revertants in the coronavirus nonstructural protein 5 protease (3CLpro) define residues involved in long-distance communication and regulation of protease activitySubstrate specificity of Tulane virus protease.Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activityDesign, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors.Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.Activation and maturation of SARS-CoV main protease.Computational modeling of the bat HKU4 coronavirus 3CL(pro) inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus.Chikungunya virus infectivity, RNA replication and non-structural polyprotein processing depend on the nsP2 protease's active site cysteine residue.
P2860
Q27490296-70618F90-6746-497D-A7DC-FB277AF7B749Q27675449-BC5045C5-33EE-42B6-82C6-5479AA11AC12Q27702869-BA0CD46A-8A86-4527-901A-9EFF0AFF76ABQ28477275-7230E09B-EA94-41D9-95B5-402E723C3EFBQ33921124-344CFA52-C420-4970-98B0-EF3B5464DD16Q34483539-F0B02152-3D25-4221-BB0B-CEFDBA6D8D7EQ34700759-A91B4321-F0D6-4124-A090-2DF51046FD60Q34709772-0247902A-5185-42B6-AC9E-2DD821B5B90BQ35065902-9ED18DEB-0454-4442-A2CE-FE8CDA954293Q35925764-EBF6B9E4-B9FF-4A6D-A11A-73D3591A5DBDQ35943856-F11BF800-8E83-471C-9A9F-58DFD635D8EAQ36532810-E7A7875E-6D85-4BE4-A940-6B8310DDA5B0Q37336376-AA25C9FA-4527-4F21-BAA6-3E253153AE2EQ37350479-B103BF9E-7CE0-4D9E-832B-FC55226C1C9EQ37481314-ABCE0604-7AA4-4A18-9D72-212648ADA792Q37870810-D452943A-E66A-459E-982B-37934107156FQ38728233-FFB08B00-6148-4507-A918-126190E6685DQ40451716-ECEDC78A-D77E-49F6-A259-081BE61FC767
P2860
Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@ast
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@en
type
label
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@ast
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@en
prefLabel
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@ast
Evaluating the 3C-like proteas ...... zed assays for drug discovery.
@en
P2093
P2860
P1433
P1476
Evaluating the 3C-like proteas ...... ized assays for drug discovery
@en
P2093
Adrian Begaye
Kiira Ratia
Susan C Baker
Valerie Grum-Tokars
P2860
P356
10.1016/J.VIRUSRES.2007.02.015
P577
2007-03-29T00:00:00Z